Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study - Khanna, D; Furst, D E; Hays, R D; Park, G S; Wong, W K; Seibold, J R; Mayes, M D; White, B; Wigley, F F; Weisman, M; Barr, W; Moreland, L; et al. (Annals of the rheumatic diseases, 2006)
Keywords: Adult; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - therapeutic use; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Clinical trials; d-Pen; d-penicillamine; Disability Evaluation; Disease; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Estimates; Extended Report; Female; Follow-Up Studies; HAQ-DI; Health Assessment Questionnaire—Disability Index; Health Status Indicators; health-related quality of life; HRQOL; Humans; Male; Medical sciences; MID; Middle Aged; minimally important difference; modified Rodnan Skin Score; mRSS; Penicillamine - administration & dosage; Penicillamine - therapeutic use; Pharmacology. Drug treatments; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Scleroderma, Diffuse - drug therapy; Scleroderma, Diffuse - rehabilitation; Severity of Illness Index; Skin; SSc; systemic sclerosis; Treatment Outcome; Sulfur containing aminoacid; Diffuse; Immunopathology; Connective tissue disease; Skin disease; Systemic disease; Rheumatology; Chelating agent; Autoimmune disease; Antirheumatic agent; Penicillamine; Scleroderma